|
|
|
|
Eupraxia Pharmaceuticals Announces Clinical and Corporate Update
|
Victoria, BC, December 18, 2023--Eupraxia Pharmaceuticals Inc., a Phase 2 clinical-stage biotechnology company, announced updates for its two clinical programs, EP-104IAR, its lead drug candidate in development for the treatment of knee osteoarthritis ("OA"), and EP-104GI, a high-potential product candidate in development for the treatment of eosinophilic esophagitis ("EoE").
|
|
|
|
|
Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial Results
|
Victoria, BC, December 14, 2023--Eupraxia Pharmaceuticals Inc., a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, announced its financial results (prepared in accordance with International Financial Reporting Standards) and operational highlights for the third quarter ended September 30, 2023.
|
|
|
|
|
Eupraxia Pharmaceuticals Reports Second Quarter 2023 Financial Results
|
Victoria, BC, August 30, 2023--Eupraxia Pharmaceuticals Inc., a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, announced its financial results (prepared in accordance with International Financial Reporting Standards) and operational highlights for the second quarter ended June 30, 2023.
|
|
|
|
|
|
|
|
|